2020
A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC).
Harding J, Abou-Alfa G, Shi Y, Whang-Peng J, Yuen M, Saif W, Tian A, Gu S, Lam W, Liu S, Cheng Y, Chu E, Yen Y. A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2020, 38: tps601-tps601. DOI: 10.1200/jco.2020.38.4_suppl.tps601.Peer-Reviewed Original ResearchProgression-free survivalHepatocellular carcinomaPrimary endpointControl armFirst-line systemic treatment optionMedian progression-free survivalTreatment-related adverse eventsCTCAE version 4.0Prior systemic therapyChronic HBV infectionDisease control rateECOG performance statusObjective response ratePlacebo-controlled studySystemic treatment optionsPhase 2 studyRate of gradeKey eligibility criteriaAdvanced hepatocellular carcinomaPotential clinical benefitTyrosine kinase inhibitorsActivation/proliferationQuality of lifeTraditional Chinese medicineAdvanced disease
2017
Pilot trial of KD018 with neo-adjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer.
Kann B, Johung K, Cheng Y, Lam W, Liu S, Decker R, Higgins S. Pilot trial of KD018 with neo-adjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Clinical Oncology 2017, 35: e15162-e15162. DOI: 10.1200/jco.2017.35.15_suppl.e15162.Peer-Reviewed Original ResearchGI toxicityRectal cancerClinical studiesGrade 3Day 1Clinical stage T3-T4Concurrent chemo-radiation therapyPilot phase I trialPathologic partial responseStandardized pharmaceutical productsAdvanced rectal cancerPhase I trialStage T3-T4Favorable toxicity profileChemo-radiation therapyFirst clinical studyFirst clinical trialTraditional Chinese medicineAbdominal RTGI ailmentsN0-N2Po bidAccrual goalCTCAE v4.0Gastrointestinal toxicity